Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 2/20 | 0.38 |
| ▸ | CCR6 | P51684 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31716990 | 0.81 | POLB (0.54) | POLBHTTL3MBTL1NPC1CYP3A4 | |
| SCHEMBL4108486 | 0.80 | L3MBTL1 (0.59) | POLBHTTL3MBTL1NPC1CYP3A4 | |
| SCHEMBL30716507 | 0.80 | L3MBTL1 (0.59) | POLBHTTL3MBTL1NPC1CYP3A4 | |
| SCHEMBL9527341 | 0.78 | LMNA (0.48) | POLBHTTL3MBTL1LMNAMAPT | |
| SCHEMBL29408211 | 0.76 | MAPT (0.50) | POLBHTTL3MBTL1LMNAMAPT | |
| SCHEMBL22658048 | 0.76 | MAPT (0.50) | POLBHTTL3MBTL1LMNAMAPT | |
| SCHEMBL4166120 | 0.75 | L3MBTL1 (0.48) | POLBHTTL3MBTL1NPC1CYP3A4 | |
| SCHEMBL9908175 | 0.74 | L3MBTL1 (0.53) | POLBHTTL3MBTL1NPC1CYP3A4 | |
| SCHEMBL9528380 | 0.74 | LMNA (0.44) | POLBHTTL3MBTL1NPC1CYP3A4 | |
| SCHEMBL8264782 | 0.73 | KDM4E (0.43) | HTTL3MBTL1NPC1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991530-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1991540-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007098214-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007098169-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | PDE7A, PDE10A, PDE7B | POLB 921/4885HTT 2397/4885L3MBTL1 4681/4885 |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | POLB 758/4885HTT 1809/4885L3MBTL1 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.